The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society

被引:37
作者
Law, MR
Palomaki, G
Alfirevic, Z
Gilbert, R
Heath, P
McCartney, C
Reid, T
Schrag, S
机构
[1] Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England
[2] Women & Infants Hosp Rhode Isl, Dept Pathol, Div Med Screening, Providence, RI USA
[3] Liverpool Womens Hosp, Liverpool L8 7SS, Merseyside, England
[4] Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England
[5] St George Hosp, Sch Med, Dept Child Hlth, London SW17 0RE, England
[6] Hlth Protect Agcy, Ctr Infect, London NW9 5HT, England
[7] Grampian Univ Hosp Trust, Dept Med Microbiol, Aberdeen AB25 2ZN, Scotland
[8] Ctr Dis Control, Atlanta, GA USA
关键词
D O I
10.1258/0969141053908366
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Streptococcus agalactiae, or Lancefield group B streptococcus (GBS), is the most frequent cause of serious bacterial sepsis, including neonatal meningitis, in UK neonates. Early-onset neonatal GBS infection, but not late-onset, can be prevented by screening to identify high-risk pregnancies and administering penicillin during delivery. g delivery. A vaccine has been developed as an alternative means of g penicillin during prevention but it is awaiting a randomized trial before being available for general use. In this review we examine the published literature to assess the morbidity and mortality attributable to neonatal GBS infection, quantify the screening performance of the two alternative modes of screening (microbiological and risk factor based), review the evidence on the efficacy of the vaccine, and estimate the numbers of deaths and cases of serious disability that each strategy in turn might prevent in the UK, in order to assess the most effective means of prevention for the UK.
引用
收藏
页码:60 / 68
页数:9
相关论文
共 55 条
[1]  
ALLEN UD, 1993, CAN MED ASSOC J, V149, P1659
[2]  
[Anonymous], 1992, Pediatrics, V90, P775
[3]  
[Anonymous], 1985, Br Med J (Clin Res Ed), V290, P778
[4]  
[Anonymous], ANTENATAL NEONATAL S
[5]  
BAKER CJ, 1981, PEDIATRICS, V68, P544
[6]   IMMUNIZATION OF PREGNANT-WOMEN WITH A POLYSACCHARIDE VACCINE OF GROUP-B STREPTOCOCCUS [J].
BAKER, CJ ;
RENCH, MA ;
EDWARDS, MS ;
CARPENTER, RJ ;
HAYS, BM ;
KASPER, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (18) :1180-1185
[7]   Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib [J].
Baker, CJ ;
Paoletti, LC ;
Wessels, MR ;
Guttormsen, HK ;
Rench, MA ;
Hickman, ME ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :142-150
[8]   CORRELATION OF MATERNAL ANTIBODY DEFICIENCY WITH SUSCEPTIBILITY TO NEONATAL GROUP-B STREPTOCOCCAL INFECTION [J].
BAKER, CJ ;
KASPER, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (14) :753-756
[9]   Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women [J].
Baker, CJ ;
Paoletti, LC ;
Rench, MA ;
Guttormsen, HK ;
Carey, VJ ;
Hickman, ME ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (04) :1129-1138
[10]   Neonatal group B streptococcal infection in South Bedfordshire, 1993-1998 [J].
Beardsall, K ;
Thompson, MH ;
Mulla, RJ .
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2000, 82 (03) :F205-F207